Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7702-6. doi: 10.1016/j.bmcl.2012.09.113. Epub 2012 Oct 23.

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.

Author information

1
AstraZeneca Respiratory & Inflammation iMED, Pepparedsleden 1, 431 83 Mölndal, Sweden. mark1.furber@astrazeneca.com

Abstract

The discovery of potent small molecule dual antagonists of the human CCR3 and H(1) receptors is described for the treatment of allergic diseases, for example, asthma and allergic rhinitis. Optimizing in vitro potency and metabolic stability, starting from a CCR1 lead compound, led to compound 20 with potent dual CCR3/H(1) activity and in vitro metabolic stability.

PMID:
23142617
DOI:
10.1016/j.bmcl.2012.09.113
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center